Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509187 | 1.00 | CYP11B1 (0.43) | CYP11B1CYP11B2SMYD3KMT2ACYP1A2 | |
| SCHEMBL8882756 | 0.92 | CYP11B1 (0.50) | CYP11B1CYP11B2SMYD3KMT2ACYP1A2 | |
| SCHEMBL29126120 | 0.81 | PARP1 (0.45) | KMT2ACYP1A2MAPTCYP2C19CA12 | |
| SCHEMBL30697324 | 0.81 | PARP1 (0.45) | KMT2ACYP1A2MAPTCYP2C19CA12 | |
| SCHEMBL26820457 | 0.80 | PARP1 (0.47) | KMT2ACYP1A2MAPTCYP2C19CA1 | |
| SCHEMBL3154045 | 0.80 | GRM5 (0.45) | KMT2ACYP1A2MAPTCYP2C19PARP1 | |
| SCHEMBL22278373 | 0.78 | CMA1 (0.56) | CYP11B1CYP11B2SMYD3KMT2ACA12 | |
| SCHEMBL14361898 | 0.78 | CYP11B1 (0.42) | CYP11B1CYP11B2SMYD3PGRTP53 | |
| SCHEMBL3594659 | 0.77 | CA9 (0.53) | CYP11B1CYP11B2SMYD3KMT2AMAPT | |
| SCHEMBL30509190 | 0.77 | AHR (0.55) | CYP11B1CYP11B2SMYD3KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116462636-A | Synthesis method of 3-alkyl quinoxaline-2 (1H) ketone compound mediated by visible light | 河南师范大学 | 2023-07-21 | — | — | CN | disclosed |
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-107072985-B | Therapeutic inhibiting compounds | 莱福斯希医药公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| EP-0590022-A1 | IMIDAZO 1,5-a]QUINOXALINES | PHARMACIA & UPJOHN COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| WO-1992022552-A1 | IMIDAZO[1,5-a]QUINOXALINES | THE UPJOHN COMPANY (US) | 1992-12-23 | — | — | WO | disclosed |
| US-RE30415-E | ANTIINFLAMMATORY AGENTS, ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-RE30314-E | ANTIINFLAMMATORY, ANTITHROMBOTIC | ELI LILLY AND COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
| US-4133884-A | Substituted pyrroloquinoxalinones and diones used in treating inflammation in warm blooded mammals | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4087527-A | ANTIINFLAMMATORY AND ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4075206-A | ANTIINFLAMMATORY, ANTITHROMBOTIC | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | CYP11B1 2457/4885CYP11B2 2560/4885SMYD3 3118/4885 |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | CYP11B1 2457/4885CYP11B2 2560/4885SMYD3 3118/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | CYP11B1 2457/4885CYP11B2 2560/4885SMYD3 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.